239 related articles for article (PubMed ID: 17136111)
1. Pleiotropic effects of the non-calcium phosphate binder sevelamer.
Nikolov IG; Joki N; Maizel J; Lacour B; Drüeke TB; Massy ZA
Kidney Int Suppl; 2006 Dec; (105):S16-23. PubMed ID: 17136111
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
3. Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
Cozzolino M; Brancaccio D
Expert Opin Emerg Drugs; 2007 Sep; 12(3):341-3. PubMed ID: 17874964
[TBL] [Abstract][Full Text] [Related]
4. A new era in phosphate binder therapy: what are the options?
Salusky IB
Kidney Int Suppl; 2006 Dec; (105):S10-5. PubMed ID: 17136110
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Cozzolino M; Brancaccio D
Int J Artif Organs; 2007 Apr; 30(4):293-300. PubMed ID: 17520565
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
9. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
10. Control of hyperphosphatemia beyond phosphate.
Evenepoel P
Kidney Int; 2007 Mar; 71(5):376-9. PubMed ID: 17315005
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
Bleyer AJ; Burke SK; Dillon M; Garrett B; Kant KS; Lynch D; Rahman SN; Schoenfeld P; Teitelbaum I; Zeig S; Slatopolsky E
Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemia and phosphate binders.
Schucker JJ; Ward KE
Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
[TBL] [Abstract][Full Text] [Related]
13. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
14. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
15. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
De Schutter TM; Behets GJ; Geryl H; Peter ME; Steppan S; Gundlach K; Passlick-Deetjen J; D'Haese PC; Neven E
Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
17. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
Brandenburg VM; Jahnen-Dechent W; Ketteler M
Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
20. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
Lin YF; Chen YM; Hung KY; Chu TS; Kan WC; Huang CY; Lin SL; Kao TW; Huang JW; Chiang WC; Yen CJ; Tsai TJ; Wu KD; Wu MS
J Formos Med Assoc; 2010 Sep; 109(9):663-72. PubMed ID: 20863994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
